Evogene and Professor Ehud Gazit of Tel Aviv University Announce a Collaboration to Develop New Therapeutics for Metabolic Diseases

Core Insights - Evogene Ltd. has entered a scientific collaboration with Professor Ehud Gazit's research group from Tel Aviv University to develop novel small molecules aimed at inhibiting pathological self-assembly processes associated with diseases like Tyrosinemia and Gout [1][3][5] Company Overview - Evogene Ltd. is a computational biology and chemistry company that utilizes big data and artificial intelligence to enhance the development of life-science products, aiming to increase success rates while reducing time and costs [6][7] Collaboration Details - The partnership will leverage Evogene's ChemPass AI technology, which focuses on generative molecular design, combined with Professor Gazit's expertise in molecular self-assembly [4][5] - The collaboration aims to create therapeutics that specifically target the self-assembly of small metabolites, potentially benefiting millions of patients suffering from related diseases [3][5] Technological Capabilities - Evogene has developed three tech-engines: MicroBoost AI, ChemPass AI, and GeneRator AI, each focusing on different aspects of product development [7] - ChemPass AI will be utilized to drive generative molecular design, creating novel molecules tailored for therapeutic efficacy [7]